We assessed the CAR-T functionality through infection efficiencies, cytokine release profiles, and effector-to-target ratios against a spectrum of B-ALL cell lines, each with varying CD19 or CD22 expression. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.